10-06-14 | 10:30 h - 11:30 h Brussels time
What are the legal aspects to consider when selecting the best entry strategy for the Japanese nanomedicine/pharmaceutical market?
The Japanese pharmaceutical market is seeing more and more foreign entrants. There are two main ways to enter the market: establishing a direct presence in Japan by setting up your own branch office or a 100% owned subsidiary, or, alternatively, forming marketing alliances including licensing agreements. There are usually many factors that together will determine the most suitable entry strategy for a company. Although the choices for market entry may be similar to those for other countries, the implications of each choice can be quite different in Japan and it is therefore important to fully understand the legal aspects of each entry option. )
The webinar is targeted at EU companies seeking to enter the Japanese nanomedicine/pharmaceutical market.
Registrations are open until the 06/06/2014 included.
What will you learn in this webinar?
In 40 minutes, from the comfort of your desk, you will discover:
- What are the legal regulations for each entry mode?
- What are the advantages and disadvantages of each entry option?
- What entry strategy have foreign companies adopted when entering the Japanese nanomedicine market?
- Expert’s Presentation
- Q&A Session
Speaker: Maths Lundin, SJC KK
Organiser: EU-Japan Centre for Industrial Cooperation - Brussels Office